FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE

• US 20130060011A1
• Filed: 08/21/2012
• Published: 03/07/2013
• Est. Priority Date: 08/23/2011
• Status: Active Application

• Current Assignee: Roche Glycart AG (Roche Holding AG)
• Original Assignee: Roche Glycart AG (Roche Holding AG)
• Inventors: Bruenker, Peter, Jaeger, Christiane, Klein, Christian, Schaefer, Wolfgang, Umana, Pablo
• Application Number:
  US13/591,010
• Publication Number:
  US 20130060011A1
• Time in Patent Office: Days
• US Class Current: 530/387.3
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/66 comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1

Abstract

The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims

1. A bispecific antibody comprising at least two fab fragments, wherein the first fab fragment comprises at least one antigen binding site specific for a first antigen;

and the second fab fragment comprises at least one antigen binding site specific for a second antigen wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and

wherein the bispecific antibody is devoid of a Fc domain.

2. The bispecific antibody of claim 1, additionally comprising a third fab fragment.

3. The bispecific antibody of claim 2, wherein the third fab fragment comprises at least one antigen binding site specific for the first or second antigen.

4. The bispecific antibody of claim 2, wherein the third fab fragment comprises at least one antigen binding site specific for the first antigen.

5. The bispecific antibody of claim 2, wherein the third fab fragment is connected to the first fab fragment.

6. The bispecific antibody of claim 5, wherein the C-terminus of the third Fab fragment is connected to the N-terminus of the first Fab fragment.

7. The bispecific antibody of claim 2, wherein the third Fab fragment is connected to the second Fab fragment.

8. The bispecific antibody of claim 7, wherein the N-terminus of the third Fab fragment is connected to the C-terminus of the first Fab fragment.

9. The bispecific antibody of claim 1 or claim 2, wherein the fab fragments are connected via a peptide linker.

10. The bispecific antibody of claim 9, wherein the peptide linker is a (G4S)2 linker.

11. A pharmaceutical composition comprising the bispecific antibody of claim 1 or claim 2.

12. A prokaryotic or eukaryotic host cell comprising vectors comprising nucleic acid molecules encoding the light chains and heavy chains of the bispecific antibody of claim 1 or claim 2.

13. A method of producing an antibody comprising culturing the host cell of claim 12 so that the antibody is produced.

14. An immunoconjugate comprising the antibody of claim 1 or claim 2 and a cytotoxic agent.